Eden Research Share Discussion Threads

[supersonico] 29/10/2017 12:54

Investing..

Majority China and Indian sponsors of the Agrow awards event??


...........................................................................



What does Indofils list of Bio pesticides (0) suggest about their motives for sponsoring a bio pesticide based event.?

Some interesting fellas on the Judging panel too..good exposure??

[supersonico] 28/10/2017 16:58

Sean Smith @

Panelists/



Last years snippets @


Agrow17 Biologicals Review/ An analysis of corporate product and regulatory news in 2016/17

[supersonico] 28/10/2017 07:12

Round Up of Bio-pesticide News

Usage of bio-pesticides growing at a faster pace than chemical variety in India

[supersonico] 27/10/2017 12:13

Bayer / China

[northwick] 26/10/2017 14:48

Wonder why one Market Maker is offering 150k shares at 10.1p?????Do they something we don't

[supersonico] 26/10/2017 14:32

Monsanto Video

[supersonico] 26/10/2017 11:27

It would be interesting to have some idea of what projections Sipcam , Eastman and Bayer have over the first five years of each product ..just conservative ball park figures would be useful. No doubt each company has it's own projections.
..............................................

MW/ Miranda/ It boils down to the Microbiome, pesticides destroy soil bacteria/Fauna in the soil and Gut bacteria/fauna in the Gut. This area of science has caught up with Monsanto etal as has the autoimmune disease and cancer epidemic . .

[investingisatrickygame] 26/10/2017 10:04

Sack Shore, pay the fee's (we have enough cash) and appoint another who can make a positive change

[attyg] 26/10/2017 08:13

Shore have simply used Sean's outlook statement, being
"current trading is in line with the Board’s expectations for the full year."
and not adjusted their own projections.

The note has no adjustments to either their (Shore's) forecasts for 2018 or 2019, despite Eden obtaining approval in France, Portugal, Cyprus and Albania and label extension to include roses in Kenya, product extensions for kiwi, aubergine and pomegranate.

Lazy "update" from Shore, most of the narrative is lifted from the text in the half year results with minor sentences inserted by Shore. No insight, no re-working of numbers in any way. Clearly produced from a few hours "work" by a junior member with no discussion with Eden's management team.

A casual examination of the figures for 2017 reveals them to be nonsensical.

Deduct the first half results from Shore's full year and we get Shore's second half. This suggests income of £600k - assume 50% GP (similar to first half, ignoring Licence fee- mix of royalties, milestone payments and product sales).
That means a GP of £300k to add to the first half £200k PBT - therefore, to generate a full year loss before tax of £1.5m Eden will incur £2m overheads in the second half. Assuming amortisation of intangible assets remains at £387k for the second half, Admin expenses would have to rise from £692k for the first half to £1.6m.
Even with the additional personnel and contracting out of tests that is far too high.

We know their will be both royalties and milestone payments in the second half - my view is that these will be higher than Shore included in their old projections for 2017.

Anyhow, the Shore note clearly has no additional input from Eden and is lazilly put out to satisfy requirements.

[investingisatrickygame] 25/10/2017 21:45

Forecast revenue of £1.7 million. That can be different from sales depending on how sales are accounted for.

[northwick] 25/10/2017 14:10

Just seen latest note from Shore capital dated 29/9, which was the same date the 1/2 yearly figures were released, in which they forecast sales of £1.7m for the year and a adjusted loss for the year of £1.5m. Are these figures credible?

[supersonico] 25/10/2017 13:22

Wise up and open your eyes Farmboy.

[supersonico] 20/10/2017 17:15

Sumiagro Tweet. ( Retweeted by Eden who have gone into Tweet overdrive)



#Mevalone prouve son efficacité contre #botrytis en Champagne dans les #vignes de Montier-en-L'isle. #biocontrole #agroécologie #viticulture


#Mevalone proves its effectiveness against #botrytis in Champagne in the #vignes of Montier-in-the isle. #biocontrole #agroécologie #viticulture

[littlealbatross2] 20/10/2017 09:51

Investing
Thank you. So, it's very much a 'Who knows, wait and see but more, probably much much more than the current paltry sp' scenario.

[investingisatrickygame] 19/10/2017 14:19

littlealbatross2

"Would anybody care to suggest what a fair take out price might"

Who knows, but you have to assume that Eden is extremely cheap at £21 million purely based on the often quoted cost and time (usually $200 million and 10 years) to develop and bring a new pesticide to market .

Here is an example at £140 million and 10 years

hxxp://www.nufarm.com/Assets/1138/1/PesticidesinPerspective.pdf

And here is the reason why Eden could be valuable on 3 AEY alone

hxxp://news.agropages.com/News/NewsDetail---14166.htm

Encapsulation, Bayer and Eastman are just a few areas to add potential material value.

Sipcam has already confirmed that they are working with Eden to develop new products and co-encapsulation to assist existing products and keep them on patent will likely appeal to the majors in this industry.

So these numbers should provide a starting point to try and understand the potential appeal and value of Eden to an industry player.

What Eden needs to do is sing from the same hymn sheet and communicate this message to a wider investment audience and get money going into its share price.

Eden would not be off message or out of sync to have investors understand this timeline and cost to others.

[littlealbatross2] 19/10/2017 12:14

A good many years ago I held shares in Axis Shield which was taken out by an American company at what many thought was a much undervalued price. Sooner or later one of the 'big boys' might have a pop at Eden whose current market cap, a paltry £21.22m. is pocket money for them.
Would anybody care to suggest what a fair take out price might be and maybe which if any of the 'big boys' might make it? I've absolutely no idea how to estimate such a fair price but I would be happy with 50p per share. Just something to do while we wait and wait and .........

[paulpaolo] 19/10/2017 10:27

That Times article says that the former minister for universities and science, Lord Willetts, who is also on the board of the Bioindustry Association trade body, says that promising UK biotech companies often list on Nasdaq, not AIM, because British investors don’t understand their tech. Potential investors in the UK ask rather too elementary questions about science, but in the USA, however, investors tend to have a doctorate in the exact subject. [I don’t understand that, perhaps he means that II’s in the USA have such people on call for advice; otherwise it doesn’t quite make sense if taken literally, sounding like wild exaggeration - but certainly ignorance of even basic science is widespread in UK]. He added that people giving up science at school after GCSE’s has led to GB City investors’ ignorance. He added that companies are being "spun out" of universities and listed on AIM etc prematurely, adding they should be matured in university laboratories for longer, and given more financial backing by uni’s.

[quazie12] 17/10/2017 20:03

Really Super !You have single handedly sent all the Eden investors to sleep on here over the last 6 months !Anyway what is there to talk about ? 3rd quarter financial update maybe ?

[supersonico] 17/10/2017 19:33

You don't half talk dull nonsense Q12.

Try and Up your game.. make it a little interesting for those who read this BB.

Ta